This research study is looking at a new way to treat hormone receptor positive (HR+), HER2 positive (HER2+) breast cancer. Normally, patients receive chemotherapy and HER2-targeted therapy first, followed by endocrine therapy and surgery. This study will test if giving endocrine therapy at the same time as chemotherapy and HER2-targeted therapy, called "Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy," improves how well patients respond to treatment before surgery. You may be able to join if you are an adult over 18 with newly diagnosed, previously untreated HR+, HER2+ breast cancer. The study aims to enroll 30 participants and will measure the complete response rate (pCR Rates) at 21 months to see if the new approach is successful. The current recruitment status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 30 participants, but the phase of the study is not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, pCR Rates, will be measured at 21 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.